Risk of gastrointestinal bleeding associated with oral anticoagulants: Population based retrospective cohort study

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Chang, Hsien Yen ^a   Zhou, Meijia ^a   Tang, Wenze ^b   Alexander, G Caleb ^a,c   Singh, Sonal ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPARATIVE STUDY; INCIDENCE; OBSERVATIONAL STUDY; ORAL DRUG ADMINISTRATION; RISK FACTOR; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DABIGATRAN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORPHOLINES; OBSERVATIONAL STUDIES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; RIVAROXABAN; THIOPHENES; UNITED STATES; WARFARIN;

EID: 84949115444     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/BMJ.h1585     Document Type: Article

References (33)

1. Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012;5:615-21.
2. Boehringer Ingelheim Pharmaceuticals. Pradaxa [package insert]. 2011.
3. Janssen Pharmaceuticals. Xarelto [package insert]. 2011.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
5. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
6. Laliberte F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-25.
7. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014;127:650-6.
8. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 2013;3:e002758.
9. Sherid M, Sifuentes H, Sulaiman S, et al. Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban. Digestion 2014;90:137-46.
10. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179-87.
11. Hopper AD, Sanders DS. Upper GI bleeding requires prompt investigation. Practitioner 2011;255:15-9.
12. Hearnshaw SA, Logan RF, Lowe D, et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011;60:1327-35.
13. Gallagher AM, van Staa TP, Murray-Thomas T, et al. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open 2014;4:e003839.
14. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012;366:864-6.
15. Desai J, Kolb JM, Weitz JI, et al. Gastrointestinal bleeding with the new oral anticoagulants-defining the issues and the management strategies. Thromb Haemost 2013;110:205-12.
16. IMS Health Incorporated or its affiliates. LifeLink® Health Plan claims data user guide & data dictionary. 2012.http://tri.uams.edu/wp-content/uploads/2011/10/LifeLink-Health-Plan-Claims-Data- Dictionary-June-2012.pdf.
17. Cowen ME, Dusseau DJ, Toth BG, et al. Casemix adjustment of managed care claims data using the clinical classification for health policy research method. Med Care 1998;36:1108-13.
18. Abraham NS, Hartman C, Richardson P, et al. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients. Circulation 2013;128:1869-77.
19. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424.
20. Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods 2010;15:234-49.
21. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006;163:262-70.
22. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
23. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993;80:557-72.
24. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100.
25. Deitelzweig SB, Pinsky B, Buysman E, et al. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther 2013;35:1536-45.
26. Hippisley-Cox J, Coupland C. Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores. BMJ 2014;349:g4606.
27. Holster IL, Valkhoff VE, Kuipers EJ, et al. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013;145:105-12.
28. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation 2015;131:157-64.
29. Bytzer P, Connolly SJ, Yang S, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol 2013;11:246-52.
30. Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ 2014;349:g4517.
31. Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014;349:g4670.
32. Maclure M, Fireman B, Nelson JC, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf 2012;21(suppl 1):50-61.
33. Ho MH, Ho CW, Cheung E, et al. Continuation of dabigatran therapy in "real-world" practice in Hong Kong. PLoS One 2014;9:e101245.